Digestive Diseases and Sciences

, Volume 58, Issue 1, pp 209–215 | Cite as

Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice

  • Seema A. Patil
  • Ankur Rustgi
  • Patricia Langenberg
  • Raymond K. Cross
Original Article



The three Food and Drug Administration (FDA)-approved anti-tumor necrosis factor drugs (anti-TNFs) for Crohn’s disease (CD) have not been directly compared.


To compare the efficacy of the three anti-TNFs for CD in clinical practice.


Retrospective review of patients initiated on anti-TNF between 2004 and 2008. Disease activity, quality of life, and remission rates were compared between groups over 1 year.


Sixty patients with CD were initiated on anti-TNF from 2004 to 2008: 31 on infliximab (IFX) and 29 on adalimumab (ADA) or certolizumab pegol (CTZ). More patients in the ADA/CTZ scores group had prior exposure to anti-TNF (76 versus 10 %, p < 0.01). Mean Harvey–Bradshaw Index (HBI) scores in the IFX group were lower than in the ADA/CTZ group at 12 months (2.72 ± 3.34 versus 5.63 ± 5.33, p = 0.03). At 12 months, more IFX patients were in remission compared with those on ADA/CTZ (88 versus 53 %, p ≤ 0.01). Mean Short Inflammatory Bowel Disease Questionnaire (SIBDQ) scores were not different between the IFX and ADA/CTZ groups at 12 months. Stratified analyses and logistic regression based on prior anti-TNF use did not show differences in remission rates at any time point post-baseline between groups.


After adjustment for prior anti-TNF there was no difference in remission rates between the IFX and ADA/CTZ groups at any time point post-baseline. This suggests that differences between groups were accounted for by a higher rate of prior anti-TNF in the ADA/CTZ group. Our results should be reviewed with caution given the small sample size.


Crohn’s disease Anti-TNF therapy Infliximab Adalimumab Certolizumab pegol 



Crohn’s disease


Inflammatory bowel disease


Extraintestinal manifestations






Certolizumab pegol


Harvey–Bradshaw Index


Short Inflammatory Bowel Disease Questionnaire


Crohn’s Disease Activity Index


Inflammatory Bowel Disease Questionnaire




  1. 1.
    Van Deventer SJH. Tumor necrosis factor and Crohn’s disease. Gut. 1997;40:443–448.PubMedGoogle Scholar
  2. 2.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohns disease cA2 study group. N Engl J Med. 1997;337:1029–1035.PubMedCrossRefGoogle Scholar
  3. 3.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.PubMedCrossRefGoogle Scholar
  4. 4.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.PubMedCrossRefGoogle Scholar
  5. 5.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.PubMedCrossRefGoogle Scholar
  6. 6.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.PubMedCrossRefGoogle Scholar
  7. 7.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.PubMedGoogle Scholar
  9. 9.
    Nesbitt A, Fossatti G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323–1332.PubMedCrossRefGoogle Scholar
  10. 10.
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.PubMedCrossRefGoogle Scholar
  11. 11.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250.PubMedCrossRefGoogle Scholar
  12. 12.
    Lichtenstein G, Thomsen O, et al. Long-term remission with Certolizumab Pegol in Crohn’s disease over 3.5 Years: results from the PRECiSE 3 study. Am J Gastroenterol. 2009;104:S450.CrossRefGoogle Scholar
  13. 13.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608.PubMedCrossRefGoogle Scholar
  14. 14.
    Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–1640.PubMedCrossRefGoogle Scholar
  15. 15.
    Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel diseases: controversies, consensus, and implications. Gut. 2006;55:749–753.PubMedCrossRefGoogle Scholar
  16. 16.
    Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–363.PubMedCrossRefGoogle Scholar
  17. 17.
    Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921–2928.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Seema A. Patil
    • 1
  • Ankur Rustgi
    • 1
  • Patricia Langenberg
    • 2
  • Raymond K. Cross
    • 1
    • 3
  1. 1.Division of Gastroenterology and Hepatology, Department of MedicineUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Department of Epidemiology and Public Health, School of MedicineUniversity of MarylandBaltimoreUSA
  3. 3.Veterans Affairs, Maryland Heath Care SystemBaltimoreUSA

Personalised recommendations